Monoamine oxidase B as a context-dependent metabolic switch in hepatocellular carcinoma

Abstract

Monoamine oxidase B (MAO-B) is a flavin enzyme on the outer mitochondrial membrane that produces hydrogen peroxide during amine deamination and has been implicated as a pro-tumorigenic redox driver in several cancers. Hepatocellular carcinoma (HCC) represents a mechanistic exception: in hepatocytes, MAO-B also catalyzes the oxidation of geranylgeraniol to geranylgeranoic acid (GGA), an acyclic retinoid-like metabolite that, in experimental models, has been shown to eliminate premalignant hepatocyte clones via apoptosis, autophagy, or pyroptosis-like inflammatory cell death. It is hypothesized that the loss of MAO-B expression in aging and chronic liver disease may contribute to a state of relative “GGA insufficiency,” only partially buffered by alternative oxidases, thereby enabling dysplastic hepatocytes to escape elimination and progress to HCC. This perspective reframes MAO-B as a context-dependent metabolic switch and outlines testable implications for biomarker development and chemoprevention in high-risk liver disease.

Keywords

Monoamine oxidase B / Hepatocellular carcinoma / Geranylgeranoic acid / Geranylgeraniol / Oxidative stress / Chemoprevention

Acknowledgements

None.

Funding

None.

Conflict of interest

The author declares no conflicts of interest.

Author contributions

This is a single-authored article.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Not applicable.

References

[1] Edmondson DE. Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications. Curr Pharm Des. 2014; 20(2): 155-160. doi: 10.2174/13816128113190990406

[2] Wei J, Wu BJ. Targeting Monoamine Oxidases in Cancer: Advances and Opportunities. Trends Mol Med. 2025; 31(4): 479-491. doi: 10.1016/j.molmed.2024.09.010

[3] Liu Y, Li D, Xie C, Pan Y, Shi Q. Monoamine Oxidase B in Cancers: Implications for Therapeutics and Prognosis. J Inflamm Res. 2025; 18: 15555-15586. doi: 10.2147/JIR.S541110

[4] Samant H, Amiri HS, Zibari GB. Addressing the Worldwide Hepatocellular Carcinoma: Epidemiology, Prevention and Management. J Gastrointest Oncol. 2021; 12(suppl 2): S318-S329. doi: 10.21037/jgo.2020.02.08

[5] Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive Strategies in Hepatocellular Carcinoma. Nat Rev Gastroenterol Hepatol. 2014; 11(1): 45-54. doi: 10.1038/nrgastro.2013.143

[6] Schwenk S, Kaplan DE. Chemoprevention of Hepatocellular Carcinoma. Hepatol Commun. 2025; 9(5): e0836. doi: 10.1097/HC9.0000000000000836

[7] Tabata Y. Endogenous and Dietary Geranylgeranoic Acid: A Mini Review on Its Role in Hepatic Tumor Suppression. Eurasian J Med Oncol. 2025; 9(4): 356-361. doi: 10.36922/EJMO025330352

[8] Mitake M, Shidoji Y. Geranylgeraniol Oxidase Activity Involved in Oxidative Formation of Geranylgeranoic Acid in Human Hepatoma Cells. Biomed Res. 2012; 33(1): 15-24. doi: 10.2220/biomedres.33.15

[9] Shidoji Y, Nakamura N, Moriwaki H, Muto Y. Rapid Loss in the Mitochondrial Membrane Potential during Geranylgeranoic Acid-Induced Apoptosis. Biochem Biophys Res Commun. 1997; 230(1): 58-63. doi: 10.1006/bbrc.1996.5883

[10] Yabuta S, Shidoji Y. TLR4-Mediated Pyroptosis in Human Hepatoma-Derived HuH-7 Cells Induced by a Branched-Chain Polyunsaturated Fatty Acid, Geranylgeranoic Acid. Biosci Rep. 2020; 40(5): BSR20194118. doi: 10.1042/BSR20194118

[11] Ho KH, Lin YW, Huang HC, et al. MAOB Promotes ROS-Mediated DNA Damage, Triggering a Cyclic MAOB-HNF1A-53BP1-P53 Axis That Suppresses the Malignancy of Clear Cell Renal Cell Carcinoma. Redox Biol. 2025; 88: 103945. doi: 10.1016/j.redox.2025.103945

[12] Diep YN, Park HJ, Kwon JH, et al. Astrocytic Scar Restricting Glioblastoma via Glutamate-MAO-B Activity in Glioblastoma-Microglia Assembloid. Biomater Res. 2023; 27(1): 71. doi: 10.1186/s40824-023-00408-4

[13] Sharpe MA, Baskin DS. Monoamine Oxidase B Levels Are Highly Expressed in Human Gliomas and Are Correlated with the Expression of HiF-1α and with Transcription Factors Sp1 and Sp3. Oncotarget. 2016; 7(3): 3379-3393. doi: 10.18632/oncotarget.6582

[14] Pu T, Wang J, Wei J, et al. Stromal-Derived MAOB Promotes Prostate Cancer Growth and Progression. Sci Adv. 2024; 10(25): eadi4935. doi: 10.1126/sciadv.adi4935

[15] Yang YC, Chien MH, Lai TC, et al. Monoamine Oxidase B Expression Correlates with a Poor Prognosis in Colorectal Cancer Patients and Is Significantly Associated with Epithelial-to-Mesenchymal Transition-Related Gene Signatures. Int J Mol Sci. 2020; 21(8): 2813. doi: 10.3390/ijms21082813

[16] Sblano S, Boccarelli A, Deruvo C, et al. The Potential of MAO Inhibitors as Chemotherapeutics in Cancer: A Literature Survey. Eur J Med Chem. 2025; 283: 117159. doi: 10.1016/j.ejmech.2024.117159

[17] Guerra B, Recio C, Aranda-Tavío H, Guerra-Rodríguez M, García-Castellano JM, Fernández-Pérez L. The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Front Oncol. 2021; 11: 626971. doi: 10.3389/fonc.2021.626971

[18] Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer Analysis Project. Nat Genet. 2013; 45(10): 1113-1120. doi: 10.1038/ng.2764

[19] Elhanani O, Ben-Uri R, Keren L. Spatial Profiling Technologies Illuminate the Tumor Microenvironment. Cancer Cell. 2023; 41(3): 404-420. doi: 10.1016/j.ccell.2023.01.010